LOGIN  |  REGISTER
Surmodics

Inozyme Pharma (NASDAQ: INZY) Stock Quote

Last Trade: US$7.66 0.27 3.65
Volume: 1,250,513
5-Day Change: 29.61%
YTD Change: 79.81%
Market Cap: US$473.160M

Latest News From Inozyme Pharma

Company to host conference call and webcast featuring key opinion leaders on Monday, April 8, 2024 at 8:00 a.m. ET BOSTON, March 26, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it will host a... Read More
Topline data from ongoing Phase 1/2 trials of INZ-701 in adults with ABCC6 Deficiency and ENPP1 Deficiency expected in early April Phase 1 trial of INZ-701 in end-stage kidney disease (ESKD) patients receiving hemodialysis (SEAPORT-1) now underway (NCT06283589), with topline data expected in Q4 2024 Launched global patient registry (PROPEL) in partnership with GACI Global to advance understanding of ENPP1 Deficiency and... Read More
BOSTON, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Douglas A. Treco, Ph.D., the Company’s chief executive officer and chairman of the board, will participate in an Orphan Bone & Neuromuscular... Read More
BOSTON, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it granted stock options to four new employees to purchase shares of the Company’s common stock, pursuant to the Company’s 2023 Inducement... Read More
BOSTON, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it granted stock options to a new employee to purchase shares of the Company’s common stock, pursuant to the Company’s 2023 Inducement Stock... Read More
BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that Douglas A. Treco, Ph.D., the Company’s chief executive officer and chairman of the board, will participate at the following investor... Read More
Patient recruitment underway in ENERGY-3 Pivotal Trial of INZ-701 in pediatric patients with ENPP1 Deficiency; topline data expected mid-2025 Topline data readouts from ongoing Phase 1/2 trials of INZ-701 in adults with ABCC6 Deficiency and ENPP1 Deficiency expected in first quarter of 2024 Cash, cash equivalents, and short-term investments as of September 30, 2023 expected to fund operations into the fourth quarter of 2025... Read More
BOSTON, Nov. 03, 2023 (GLOBE NEWSWIRE) - - Inozyme Pharma, Inc. (Nasdaq: INZY)(“Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it granted stock options to new employees to purchase shares of the Company’s common stock, pursuant to the Company’s 2023 Inducement Stock... Read More
BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced an oral presentation at the American Society of Nephrology (ASN) Kidney Week 2023, which is being held November 2-5, 2023 in Philadelphia, PA.... Read More
BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, highlighted the inclusion of Generalized Arterial Calcification of Infancy (GACI), which is caused by mutations in the ENPP1 or ABCC6 genes, in the Genomic... Read More
BOSTON, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it will present three posters at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting, which is being held... Read More
Data from ongoing trial suggest clinical benefit for ENPP1 Deficiency, including improvement in key biomarkers, patient reported outcomes (PROs) and functional outcomes Improvement in the Global Impression of Change (GIC) observed in all three dose cohorts in ABCC6 Deficiency (PXE) trial INZ-701 was generally well tolerated and exhibited a favorable safety and immunogenicity profile in both trials Company to host conference... Read More
BOSTON, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY)(“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it will host an Investor and Analyst Event on Tuesday, September 26, 2023 at 8:00 a.m. Eastern Time. During the webcast and conference... Read More
BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY)(“Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it granted stock options to a new employee to purchase shares of the Company’s common stock, pursuant to the Company’s 2023 Inducement Stock... Read More
BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Douglas A. Treco, Ph.D., the company’s chief executive officer and chairman of the board, will present at the H.C. Wainwright 25th Annual Global Investment Conference on... Read More
Interim data readouts from ongoing Phase 1/2 trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency expected in September 2023 Plasma pyrophosphate (PPi) to serve as primary endpoint in the U.S. and co-primary endpoint in the EU for ENERGY-3 pediatric pivotal trial for ENPP1 Deficiency; initiation expected in October 2023 Cash, cash equivalents, and short-term investments as of June 30, 2023, together with... Read More
BOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc . (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that the Company granted stock options to new employees to purchase shares of the Company’s common stock, pursuant to the Company’s 2023 Inducement Stock Incentive Plan,... Read More
BOSTON, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced the closing of its underwritten public offering of 14,375,000 shares of its common stock at a price of $4.80 per share. The shares of common stock issued and sold in the... Read More
BOSTON, July 27, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced the pricing of an underwritten public offering of 12,500,000 shares of its common stock at a price of $4.80 per share, for aggregate gross proceeds of approximately $60... Read More
BOSTON, July 27, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it is commencing an underwritten public offering of $60,000,000 of shares of its common stock. In addition, Inozyme intends to grant the underwriters an option for a... Read More
Change in plasma pyrophosphate (PPi) as primary endpoint in the U.S. and co-primary endpoint in the EU for planned ENERGY-3 pivotal trial in pediatric patients ENERGY-3 pivotal trial in pediatric patients expected to initiate in October 2023, topline data expected to be reported in mid-2025 Updated cash runway expected to fund cash flow requirements into Q1 2025 Company to host conference call today at 8am ET BOSTON, July... Read More
Conference call and webcast to be held on July 26, 2023, at 8am ET BOSTON, July 19, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it will host a conference call to provide an update on the Company’s... Read More
BOSTON, June 27, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced dosing of the first patient in its ENERGY-1 trial, a Phase 1b clinical trial of INZ-701 in infants with ENPP1 Deficiency. “Initiation of the ENERGY-1 trial in infants is an... Read More
BOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Douglas A. Treco, Ph.D., the company’s chief executive officer and chairman of the board, will present at the Jefferies Healthcare Conference on Friday, June 9, 2023, from... Read More
Upcoming clinical and regulatory milestones remain on track with previous guidance Current cash, cash equivalents and short-term investments anticipated to fund cash flow requirements into the fourth quarter of 2024 BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization... Read More
BOSTON, May 03, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc . (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that the Company granted stock options to new employees to purchase shares of the Company’s common stock, pursuant to the Company’s 2023 Inducement Stock Incentive Plan,... Read More
BOSTON, April 14, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Yves Sabbagh, Ph.D., the company’s senior vice president and chief scientific officer, will present recently announced preliminary data from the ongoing Phase 1/2 clinical... Read More
BOSTON, April 11, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical- stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Douglas A. Treco, Ph.D., the company’s chief executive officer and chairman of the board, will participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare... Read More
BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced the grant of an inducement award outside of the Company’s 2020 Stock Incentive Plan to its newly appointed Chief Operations Officer, Matthew Winton, Ph.D. The inducement... Read More
Founding CEO, Axel Bolte, MSc, MBA, to retire; Douglas A. Treco, Ph.D., to succeed as CEO Matthew Winton, Ph.D., appointed COO Upcoming clinical and regulatory milestones remain on track with previous guidance Current cash, cash equivalents and short-term investments anticipated to fund cash flow requirement into the fourth quarter of 2024 BOSTON, March 22, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a... Read More
BOSTON, March 01, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief executive officer, will participate in the Neuromuscular and Bone Panel presentation at the Cowen 43rd... Read More
Rapid, significant, and sustained increase in plasma pyrophosphate (PPi) observed and encouraging patient reported outcome data in all dose cohorts in ENPP1 Deficiency trial Rapid and significant increase in PPi observed in all dose cohorts with sustained increase observed in highest dose cohort in ABCC6 Deficiency (PXE) trial INZ-701 was generally well-tolerated and exhibited a favorable safety profile in both trials... Read More
Company to share topline data from ongoing Phase 1/2 trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency (PXE) BOSTON, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it will host an Investor and Analyst Event on... Read More
Company to share topline data from ongoing Phase 1/2 trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency at virtual event on Thursday, Feb. 16, 2023 Significant clinical and scientific milestones across ENPP1 Deficiency and ABCC6 Deficiency programs achieved in 2022 BOSTON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel... Read More
Article in Orphanet Journal of Rare Diseases estimates genetic prevalence of ENPP1 Deficiency at 1 in 64,000 pregnancies, more than tripling prior estimate Company estimates addressable patient population with ENPP1 Deficiency at 37,000 worldwide; 2,800 in North America, 4,100 in Europe and 900 in Japan BOSTON, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease... Read More
C4 Therapeutics

COPYRIGHT ©2023 HEALTH STOCKS HUB